The role of modelling in prioritising and planning clinical trials
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: To identify the role of modelling in planning and prioritising trials. The review focuses on modelling methods used in the construction of disease models and on methods for their analysis and interpretation. DATA SOURCES: Searches were initially developed in MEDLINE and then translated into other databases. REVIEW METHODS: Systematic reviews of the methodological and case study literature were undertaken. Search strategies focused on the intersection between three domains: modelling, health technology assessment and prioritisation. RESULTS: The review found that modelling can extend the validity of trials by: generalising from trial populations to specific target groups; generalising to other settings and countries; extrapolating trial outcomes to the longer term; linking intermediate outcome measures to final outcomes; extending analysis to the relevant comparators; adjusting for prognostic factors in trials; and synthesising research results. The review suggested that modelling may offer greatest benefits where the impact of a technology occurs over a long duration, where disease/technology characteristics are not observable, where there are long lead times in research, or for rapidly changing technologies. It was also found that modelling can inform the key parameters for research: sample size, trial duration and population characteristics. One-way, multi-way and threshold sensitivity analysis have been used in informing these aspects but are flawed. The payback approach has been piloted and while there have been weaknesses in its implementation, the approach does have potential. Expected value of information analysis is the only existing methodology that has been applied in practice and can address all these issues. The potential benefit of this methodology is that the value of research is directly related to its impact on technology commissioning decisions, and is demonstrated in real and absolute rather than relative terms; it assesses the technical efficiency of different types of research. Modelling is not a substitute for data collection. However, modelling can identify trial designs of low priority in informing health technology commissioning decisions. CONCLUSIONS: Good practice in undertaking and reporting economic modelling studies requires further dissemination and support, specifically in sensitivity analyses, model validation and the reporting of assumptions. Case studies of the payback approach using stochastic sensitivity analyses should be developed. Use of overall expected value of perfect information should be encouraged in modelling studies seeking to inform prioritisation and planning of health technology assessments. Research is required to assess if the potential benefits of value of information analysis can be realised in practice; on the definition of an adequate objective function; on methods for analysing computationally expensive models; and on methods for updating prior probability distributions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tversky, A., & Kahneman, D. (1974) · Science · doi:10.1126/science.185.4157.1124 · Cited by 28,810
Moher, D., Jadad, A. R., Nichol, G., Penman, M., Tugwell, P., & Walsh, S. (1995) · Controlled Clinical Trials · doi:10.1016/0197-2456(94)00031-w · Cited by 1,308
The Markov process in medical prognosis
Beck, J. R., & Pauker, S. G. (1983) · Medical Decision Making · doi:10.1177/0272989x8300300403 · Cited by 957
Formulating Questions and Locating Primary Studies for Inclusion in Systematic Reviews
Counsell, C. (1997) · Annals of Internal Medicine · doi:10.7326/0003-4819-127-5-199709010-00008 · Cited by 505
Cited by
Systematic reviews in the social sciences: a practical guide
(2006) · Choice Reviews Online · doi:10.5860/choice.43-5664 · Cited by 4,089
Bower, P., & Gilbody, S. (2005) · British Journal of Psychiatry · doi:10.1192/bjp.186.1.11 · Cited by 1,084
Searching for and selecting studies
Lefebvre, C., Glanville, J., Briscoe, S., Littlewood, A., Marshall, C., Metzendorf, M., Noel‐Storr, A., Rader, T., Shokraneh, F., Thomas, J., et al. (2019) · Cochrane Handbook for Systematic Reviews of Interventions · doi:10.1002/9781119536604.ch4 · Cited by 647
A taxonomy of model structures for economic evaluation of health technologies
Brennan, A., Chick, S. E., & Davies, R. (2006) · Health Economics · doi:10.1002/hec.1148 · Cited by 555
Self-citationA cost minimisation analysis in teledermatology: model-based approach
Eminović, N., Dijkgraaf, M. G., Berghout, R. M., Prins, A. H., Bindels, P. J., & de Keizer, N. F. (2010) · BMC Health Services Research · doi:10.1186/1472-6963-10-251 · Cited by 86
“The economic evaluation was performed following a decision analytical approach [8].”
Method
Metadata
- Authors
- Chilcott, J., Brennan, A., Booth, A., Karnon, J., & Tappenden, P.
- Venue
- Health Technology Assessment
- Published
- 2003-08
- Volume
- 7
- Issue
- 23
- Pages
- iii, 1-125
- ISSN
- 1366-5278 (ISSN-L)
- 2046-4924
- OpenAlex
- W2087025145
- Cited by
- 98
- References
- 4
- FWCI
- 14.32
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The role of modelling in prioritising and planning clinical trials. https://app.cochat.ai/papers/10.3310/hta7230
- The paper
- Chilcott, J., Brennan, A., Booth, A., Karnon, J., & Tappenden, P. (2003). The role of modelling in prioritising and planning clinical trials. Health Technology Assessment. https://doi.org/10.3310/hta7230
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.